Seattle’s Infectious Disease Research Institute is working with Houston’s Baylor College of Medicine to multiply the doses of a potential COVID-19 vaccine by 30 to 100 times. Other partners in the effort include Seattle-based PATH and Texas Children’s Hospital Center for Vaccine Development. If the project proceeds as planned, Baylor and its partners could repurpose a vaccine candidate originally created to counter a different coronavirus-based disease known…
Read More
About 1% of kids who visited a Seattle hospital in April had been infected with the novel coronavirus, according to the first large-scale survey for antibodies in children. The study also found most of the youngsters developed a robust immune response, an encouraging sign for a future vaccine. “If children can respond to the virus, then children can respond to…
Read More
People with autism spectrum disorder, or ASD, may experience sensory hypersensitivity more often than people without ASD, according to the National Autism Association. Among other responses, this hypersensitivity can lead to “sensory overload,” when sensory systems like vision or hearing are “overwhelmed” by stimuli. Scientists do not fully understand the differences in how sensory systems perceive and process stimuli in…
Read More
Seattle Children’s Research Institute, one of the top pediatric research institutions in the world, and global biotechnology leader CSL Behring announced a strategic alliance to develop stem cell gene therapies for primary immunodeficiency diseases. Initially, the alliance will focus on the development of treatment options for patients with two rare, life-threatening primary immunodeficiency diseases — Wiskott-Aldrich Syndrome and X-linked Agammaglobulinemia. These are…
Read More
In cancer, it’s tempting to divide genes into two camps: those that suppress cancer and those that drive it. But cancer is more complicated. In a recent study, investigators at Fred Hutchinson Cancer Research Center showed how the same gene can restrain tumor growth or promote it, depending on its accompanying mutations. The findings highlight the idea that “context really determines…
Read More
CTI BioPharma Corp. today announced that it has enrolled the first patient in the Phase 3 PRE-VENT trial (NCT04404361) of pacritinib in hospitalized patients with severe COVID-19. PRE-VENT, a randomized, double-blind, placebo-controlled multicenter study, will compare pacritinib plus standard of care versus placebo and standard of care in 358 hospitalized patients with severe COVID-19, including patients with and without cancer.…
Read More
Seattle Genetics, Inc. today announced positive results from exploratory analyses of intracranial efficacy, including survival, in patients with HER2-positive metastatic breast cancer (MBC) who had stable or active brain metastases in the HER2CLIMB pivotal trial of TUKYSA™ (tucatinib). HER2CLIMB compared TUKYSA in combination with trastuzumab and capecitabine to trastuzumab and capecitabine alone in patients with unresectable, locally advanced or metastatic HER2-positive…
Read More
When Dr. Janet Englund (pictured), a member of the Center for Clinical Translational Research at Seattle Children’s Research Institute, received news in late February that a Seattle Children’s patient had tested positive for the novel coronavirus and represented the first example of community transmission in Washington state, she knew things as we knew them were never going to be the same. Englund, who has…
Read More

Teaming Up with Virginia Mason for Rapid COVID-19 Research

Scientists at Benaroya Research Institute at Virginia Mason (BRI) are studying COVID-19 patient blood samples to understand the immune response to this deadly virus. With more than 30 Virginia Mason team members and BRI researchers collaborating, research is happening at an unprecedented pace to help combat the COVID-19 public health crisis. By examining these samples, researchers are aiming to learn…
Read More